fashion -WSS

fashion

author：explore 2025-09-03 03:28:00 - browse：355

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Stigma and the return of syphilis

focus

WSS

Do more moles mean more problems? Not so, says new study

Adam's Biotech Scorecard: Do Sarepta's exon

Focused ultrasound for uterine fibroids: an uphill battle

Bill would stop addiction treatment from triggering child abuse inquiry

Prosthetic arm enables patients to feel the objects they grip

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Wikipedia

fashion

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Activists slam private health insurers over coverage restrictions

David Sabatini, ex

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Chan Zuckerberg Biohub Chicago to focus on inflammation

Novavax promises a turnaround & Lilly roils the obesity market

Health insurers say they are turning to AI to cut costs, improve care

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

First Opinion Podcast: What happens when kids become caregivers?

entertainment

Startling documents reveal new facets of Sacklers' opioid empire

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Why age limits for politicians are a terrible idea

What will save rural psychiatry services? Higher Medicaid payments

First Opinion Podcast: What happens when kids become caregivers?

Liquid biopsy for lung cancer is launched by Delfi

hotspot

entertainment

focus

Wikipedia